When you’re angling for acquisition by Big Pharma, your IP is everything. And if you’re using AI in your drug-discovery pipeline, you need to be aware of the risks—and how to navigate them.
Fenwick’s Antonia Sequeira and Fredrick Tsang explore considerations for companies large and small that are innovating in this space.
- Ensure that a human makes a “significant” contribution to the discovery
- Closely review any third-party AI solutions you may use
- Assess and understand any tools your employees use
